To include your compound in the COVID-19 Resource Center, submit it here.

Santen reports Phase I/II safety data for wet AMD candidate

Santen Pharmaceutical Co. Ltd. (Tokyo:4536) reported data from a Phase I/II trial in 12 patients with wet age-related

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE